TAR-210

COMBINATION_PRODUCT2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Non-Muscle Invasive Bladder Neoplasms

Phase 3

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

RecruitingNCT06319820

Janssen Research & Development, LLCNon-Muscle Invasive Bladder Neoplasms

Start: 2024-04-18End: 2032-12-31Target: 641Updated: 2026-03-13

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

RecruitingNCT06919965

Janssen Research & Development, LLCNon-Muscle Invasive Bladder Neoplasms

Start: 2025-09-10End: 2032-03-16Target: 220Updated: 2026-03-13

Related Papers

Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle‐Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial

The Journal of Urology2025-03-064 citations